Hormonal Cancer Therapies

Hormonal cancer therapy exploits a dependency: certain tumors carry receptors that, when bound by estrogen or androgen, drive proliferation. Blocking the hormone or its receptor starves the tumor of a growth signal. Because not every tumor of a given type expresses these receptors, testing biopsy tissue is mandatory before starting therapy — a receptor-negative tumor will not respond.

Breast Cancer: Estrogen Pathway

Selective estrogen receptor modulators (SERMs) act differently across tissues. Tamoxifen blocks estrogen receptors in breast tissue (antagonist) while activating them in bone and endometrium (agonist). This duality explains its risk-benefit profile: it preserves bone density, but the same agonist activity on endometrium raises endometrial cancer risk and increases venous thromboembolism risk. Hot flashes are common from systemic estrogen blockade. Tamoxifen is a prodrug requiring CYP2D6 conversion to its active metabolite, so strong CYP2D6 inhibitors (certain SSRIs used for mood or hot flashes) can blunt its efficacy — an important interaction to screen for. Raloxifene is a SERM with less endometrial stimulation, used mainly for risk reduction.

Aromatase inhibitors (anastrozole, letrozole, exemestane) block peripheral conversion of androgens to estrogen in fat and muscle. Postmenopausal women rely on this peripheral pathway since the ovaries no longer produce estrogen directly, so these drugs work only after menopause; premenopausal ovaries would simply override the blockade. Loss of estrogen's protective effect on joints and bone produces arthralgia, accelerated bone loss, and unfavorable lipid changes.

Fulvestrant, a selective estrogen receptor degrader (SERD), binds the receptor and marks it for destruction — a pure antagonist without tamoxifen's mixed agonist activity. GnRH agonists can add ovarian suppression in premenopausal women, eliminating ovarian estrogen and creating a temporary menopausal state so aromatase inhibitors become usable.

Prostate Cancer: Androgen Pathway

Androgen deprivation therapy (ADT) is the backbone of hormone-sensitive prostate cancer treatment. GnRH agonists (leuprolide and similar agents) initially overstimulate the pituitary, causing a transient testosterone surge — the "flare" — before receptor downregulation suppresses testosterone long-term. Because the flare can worsen symptoms or stimulate tumor growth, an antiandrogen is bridged in during the first weeks. GnRH antagonists (degarelix) suppress testosterone directly without a surge, avoiding that need.

Antiandrogens block the androgen receptor itself. First-generation agents (bicalutamide) are older, used for flare coverage or alongside orchiectomy alternatives. Second-generation antiandrogens (enzalutamide, apalutamide) bind more potently and blunt receptor nuclear translocation, giving stronger suppression in more advanced disease. Abiraterone inhibits CYP17, an enzyme needed for androgen synthesis in the testes, adrenal glands, and tumor tissue itself; because CYP17 also drives cortisol synthesis, abiraterone is paired with a corticosteroid (prednisone) to prevent adrenal insufficiency.

Long-term androgen deprivation carries broad consequences: bone loss and fracture risk, metabolic syndrome features, cardiovascular risk, cognitive changes, hot flashes, and loss of libido or erectile function. Because ADT often continues for years, periodic bone density monitoring, metabolic screening, and cardiovascular risk management are built into routine care, and adherence support matters given the therapy's duration.